Cybele L R Abad1, Raymund R Razonable2. 1. Section of Infectious Diseases, Department of Medicine, Philippine General Hospital, University of the Philippines-Manila, Manila, Philippines. 2. Division of Infectious Diseases, Department of Medicine, The William J Von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota.
Abstract
BACKGROUND: Mycobacterium tuberculosis may be transmitted via the allograft to cause a morbid and potentially fatal infection after solid organ transplantation (SOT). We reviewed all reported cases of donor-derived tuberculosis (DDTB) to provide an update on its epidemiology, clinical course, and outcome after SOT. METHODS: MEDLINE, OVID, and EMBASE were reviewed from its inception until December 31, 2016 using key words donor-derived infection, tuberculosis and solid organ transplant or transplantation. RESULTS: We retrieved 36 cases of proven (n = 17), probable (n = 8), and possible (n = 11) DDTB among 16 lung, 13 kidney, 6 liver, and 1 heart recipients. Most patients were male (21/35, 60%) with median age of 48 (range 23-68) years. Median time to clinical presentation or diagnosis was 2.7 months (range 0.2-29). The most common donor risk factor was residence in a TB-endemic area (13/28, 46.4%). Fever was the most frequent presenting symptom (20/36, 56.5%). Diagnosis of tuberculosis was mostly made via AFB smear or mycobacterial culture (30/36, 83.3%). Allograft involvement was expectedly common; there were almost equal proportions of pulmonary (36%), extra-pulmonary (28%) and disseminated (36%) cases. All cases of pulmonary TB were identified only among lung transplant recipients. The median duration of TB treatment was 10.5 (range 3-24) months. Graft loss occurred in four (4/22, 18.2%) patients. All-cause mortality was 25% (9/36); four of nine deaths were attributed to TB. CONCLUSIONS: Donor-derived TB presents early after SOT, most commonly as fever, and carries a high mortality risk. Donors should be screened, with particular attention to TB risk factors. Fever during the early post-operative period should prompt a thorough evaluation for DDTB in endemic regions and among patients with "at-risk" donors.
BACKGROUND:Mycobacterium tuberculosis may be transmitted via the allograft to cause a morbid and potentially fatal infection after solid organ transplantation (SOT). We reviewed all reported cases of donor-derived tuberculosis (DDTB) to provide an update on its epidemiology, clinical course, and outcome after SOT. METHODS: MEDLINE, OVID, and EMBASE were reviewed from its inception until December 31, 2016 using key words donor-derived infection, tuberculosis and solid organ transplant or transplantation. RESULTS: We retrieved 36 cases of proven (n = 17), probable (n = 8), and possible (n = 11) DDTB among 16 lung, 13 kidney, 6 liver, and 1 heart recipients. Most patients were male (21/35, 60%) with median age of 48 (range 23-68) years. Median time to clinical presentation or diagnosis was 2.7 months (range 0.2-29). The most common donor risk factor was residence in a TB-endemic area (13/28, 46.4%). Fever was the most frequent presenting symptom (20/36, 56.5%). Diagnosis of tuberculosis was mostly made via AFB smear or mycobacterial culture (30/36, 83.3%). Allograft involvement was expectedly common; there were almost equal proportions of pulmonary (36%), extra-pulmonary (28%) and disseminated (36%) cases. All cases of pulmonary TB were identified only among lung transplant recipients. The median duration of TB treatment was 10.5 (range 3-24) months. Graft loss occurred in four (4/22, 18.2%) patients. All-cause mortality was 25% (9/36); four of nine deaths were attributed to TB. CONCLUSIONS:Donor-derived TB presents early after SOT, most commonly as fever, and carries a high mortality risk. Donors should be screened, with particular attention to TB risk factors. Fever during the early post-operative period should prompt a thorough evaluation for DDTB in endemic regions and among patients with "at-risk" donors.
Authors: Shabnum Patel; Haili Lang; Gelina Sani; Alexandra F Freeman; Jennifer Leiding; Patrick J Hanley; Conrad Russell Cruz; Melanie Grant; Yunfei Wang; Benjamin Oshrine; Cindy Palmer; Steven M Holland; Catherine M Bollard; Michael D Keller Journal: Front Immunol Date: 2019-03-29 Impact factor: 7.561
Authors: Jefferson M Jones; Holenarasipur R Vikram; Michael Lauzardo; Amy Hill; Jeffrey Jones; Clinton Haley; Barbara Seaworth; Sara Oldham; Marcus Brown; Felipe Gutierrez; Sridhar V Basavaraju Journal: Transpl Infect Dis Date: 2020-07-08
Authors: Luiz Roberto de Sousa Ulisses; Helen Souto Siqueira Cardoso; Inara Creão Costa Alves; Isabela Novais Medeiros; Camilla Garcia de Oliveira; Tiago Martins de Almeida; Fabíola Fernandes Dos Santos Castro; Claudia Neto Gonçalves Neves da Silva; Laura Viana de Lima; Renata Pereira Fontoura; Eduardo Resende Sousa E Silva; Pollyana Lopes de Araújo; Gustavo de Sousa Arantes Ferreira Journal: J Bras Nefrol Date: 2022 Jan-Mar
Authors: Alberto Mella; Filippo Mariano; Caterina Dolla; Ester Gallo; Ana Maria Manzione; Maria Cristina Di Vico; Rossana Cavallo; Francesco Giuseppe De Rosa; Cristina Costa; Luigi Biancone Journal: Biomedicines Date: 2022-03-18